Ajanta Pharma has fixed August 5, 2026, as the record date for determining shareholders eligible for its first interim dividend of ₹32 per share. The declaration follows the company’s robust Q1FY27 results, where consolidated net profit surged 31% year-on-year to ₹334 crore, while revenue from operations expanded 25% to ₹1,626 crore. This dividend payout, totaling approximately ₹400 crore, underscores management’s confidence in cash generation despite ongoing tax scrutiny and operational headwinds in certain emerging markets.

The Board of Directors approved the dividend on July 30, 2026, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors M/s B S R & Co. LLP issued an unmodified conclusion on the quarterly results. Shareholders holding equity shares on the record date will receive the dividend, with payments scheduled for August 18, 2026, or later. The company operates under an open book closure system, meaning there is no specific book closure period; eligibility is determined solely by the shareholding pattern as of the close of business on the record date.

Q1FY27 Financial Performance

Ajanta Pharma’s top-line growth was broad-based, driven primarily by exceptional performances in its US Generic and Africa Institutional segments. While India’s branded generic business grew 24% to ₹509 crore, Asia saw a 16% decline to ₹255 crore. However, these were offset by a 57% surge in US Generic revenues to ₹487 crore and an 83% jump in Africa Institutional business to ₹70 crore.

Segmental Insights and Operational Efficiency

In India, Ajanta Pharma outperformed the Indian Pharmaceutical Market (IPM) growth rate of 11% with a 15% overall growth. New launches contributed significantly, growing 76% against IPM, while volumes grew 40%. Key therapeutic areas such as Ophthalmology, Dermatology, and Pain Management all exceeded IPM growth rates. The company maintains a strong pipeline with 51 commercialized ANDAs in the US, 17 awaiting FDA approval, and 5 holding tentative approvals.

R&D expenses increased to ₹66 crore (4% of revenue) from ₹56 crore in Q1FY26, reflecting continued investment in formulation capabilities across its seven manufacturing facilities. Despite revenue growth, adjusted EBITDA margin contracted slightly from 29% to 28%, indicating that operating costs rose marginally faster than sales, although absolute earnings power improved significantly.

What the Numbers Show

The divergence between the 25% revenue growth and 31% profit growth highlights improved operational leverage and favorable mix shifts towards higher-margin US generics. The 57% surge in US revenues suggests successful market penetration or volume gains in key molecules. Furthermore, the substantial ₹400 crore dividend payout, representing over 100% of the quarterly net profit, signals strong underlying cash generation capabilities, even as the company navigates tax search operations initiated in August 2025. The impact of these searches remains unquantifiable for Q1FY27, posing a potential future risk to retained earnings.

Ajanta Pharma has revised the timing of its earnings conference call to discuss its Q1 FY27 unaudited financial results to 16:15 hrs IST on July 30, 2026. The leadership team will review the company's financial performance and take questions from investors. This discussion follows the company's board meeting and is conducted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Participants can join the discussion via specific dial-in numbers provided for domestic and international access. The company has also issued a Diamond pass link for faster connectivity, requiring prior registration to receive a calendar invite, passcode, and PIN. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.

Earnings Conference Call Details

Dial-in Information

For those unable to attend the live session, a playback of the earnings call audio will be available 120 minutes after the conclusion of the event. Additionally, a full transcript of the conference call will be accessible on the company's official website.